The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center.
COVID-19
lung cancer
pattern of treatment
wait times
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
14 11 2022
14 11 2022
Historique:
received:
14
10
2022
revised:
08
11
2022
accepted:
11
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
We have recently reported a 35% drop in new lung cancer diagnoses and a 64% drop in lung cancer surgeries during the first year of the pandemic. The target population was divided into three cohorts: pre-COVID-19 (2019), first year of COVID-19 (2020), and second year of COVID-19 (2021). The number of new lung cancer diagnoses during the second year of the pandemic increased by 75%, with more than 50% being in the advanced/metastatic stage. There was a significant increase in cases with multiple extrathoracic sites of metastases during the pandemic. During the first year of the pandemic, significantly more patients were treated with radiosurgery compared to the pre-COVID-19 year. During the second year, the number of radiosurgery and surgical cases returned to pre-COVID-19 levels. No significant changes were observed in systemic chemotherapy and targeted therapy. No statistical difference was identified in the mean wait time for diagnosis and treatment during the three years of observation. However, the wait time for surgery was prolonged compared to the pre-COVID-19 cohort. The significant drop in new diagnoses of lung cancer during the first year of the pandemic was followed by an almost two-fold increase in the second year, with the increased rate of metastatic disease with multiple extra-thoracic site metastases. Limited access to surgery resulted in the more frequent use of radiosurgery.
Sections du résumé
BACKGROUND
We have recently reported a 35% drop in new lung cancer diagnoses and a 64% drop in lung cancer surgeries during the first year of the pandemic.
METHODS
The target population was divided into three cohorts: pre-COVID-19 (2019), first year of COVID-19 (2020), and second year of COVID-19 (2021).
RESULTS
The number of new lung cancer diagnoses during the second year of the pandemic increased by 75%, with more than 50% being in the advanced/metastatic stage. There was a significant increase in cases with multiple extrathoracic sites of metastases during the pandemic. During the first year of the pandemic, significantly more patients were treated with radiosurgery compared to the pre-COVID-19 year. During the second year, the number of radiosurgery and surgical cases returned to pre-COVID-19 levels. No significant changes were observed in systemic chemotherapy and targeted therapy. No statistical difference was identified in the mean wait time for diagnosis and treatment during the three years of observation. However, the wait time for surgery was prolonged compared to the pre-COVID-19 cohort.
CONCLUSIONS
The significant drop in new diagnoses of lung cancer during the first year of the pandemic was followed by an almost two-fold increase in the second year, with the increased rate of metastatic disease with multiple extra-thoracic site metastases. Limited access to surgery resulted in the more frequent use of radiosurgery.
Identifiants
pubmed: 36421337
pii: curroncol29110684
doi: 10.3390/curroncol29110684
pmc: PMC9689557
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8677-8685Références
Thorax. 1998 Jun;53 Suppl 1:S1-8
pubmed: 9713437
Chest. 2020 Jul;158(1):406-415
pubmed: 32335067
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Can J Surg. 2021 Feb 18;64(1):E103-E107
pubmed: 33599462
Am J Clin Pathol. 2021 Mar 15;155(4):615-616
pubmed: 33382874
JCO Glob Oncol. 2021 Feb;7:311-323
pubmed: 33617304
Eur J Cardiothorac Surg. 2020 Oct 1;58(4):752-762
pubmed: 32862224
Cureus. 2020 Apr 28;12(4):e7873
pubmed: 32368429
Cancers (Basel). 2020 Aug 29;12(9):
pubmed: 32872421
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
ESMO Open. 2022 Apr;7(2):100406
pubmed: 35219245
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
JCO Clin Cancer Inform. 2020 Nov;4:1059-1071
pubmed: 33253013
Am J Clin Pathol. 2021 Jan 4;155(1):64-68
pubmed: 32995855
J Thorac Oncol. 2020 Jul;15(7):1119-1136
pubmed: 32422364
Ann Oncol. 2020 Aug;31(8):1065-1074
pubmed: 32442581
Cancer. 2000 Feb 1;88(3):701-7
pubmed: 10649266
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Clin Lung Cancer. 2022 Sep;23(6):e362-e376
pubmed: 35660355
Thorax. 2009 Sep;64(9):749-56
pubmed: 19717709